Personalizing Medication Therapy
Mental illnesses are a significant burden to individuals and their families. Moreover, the cost to the global economy is enormous — accounting for roughly one-third of the total economic burden among all non-communicable diseases, which also includes cardiovascular disease, chronic respiratory disease, cancer, and diabetes.1
To lessen the burden, medication therapy can be a crucial arm in successfully treating mental health disorders. However, healthcare providers are frequently challenged to identify which medications will work best and at what optimized dosage.2 For antidepressants alone, a range of pharmaceutical therapies with differing modes of action is available. Yet only about one-third of patients initially prescribed medication for a mental health disorder actually experience relief, leading to many months or even years of trial and error with medications and dosages.3 Additionally, adverse side effects are surprisingly common and a contributing factor in a patient’s decision to terminate their treatment plan.4-6 Pharmacogenetic testing offers a more intelligent and personalized method towards making prescription decisions.
Determine your patients’ risks to adverse reactions and therapeutic failure before they occur.
In order to identify medication responders versus non-responders, the FDA lists information on pharmacogenetic biomarkers for more than 20 medications intended for psychotropic therapy.7 Additionally, the Clinical Pharmacogenetic Implementation Consortium (CPIC), recently issued guidelines for the dosing of tricyclic antidepressants that take genetic marker information into account.8 Both sources highlight the emerging role that pharmacogenetic testing plays in making targeted mental health treatment decisions.
Kashi’s Psychotropic Panel gives healthcare providers the genetic information they need to select the best psychiatric medications and dosing regimens to greatly improve their patient’s health and quality of life.
Benefits of Kashi’s Psychotropic PGx Panel
- Reduced trial-and-error period in finding an effective medication
- Faster identification of patients who are at an elevated risk of experiencing side effects or therapeutic failure
- Reduce adverse drug risks resulting from polypharmacy
Gene Tests Included in the Kashi’s Psychotropic PGx Panel
|GENE TESTS||EFFECT ON MENTAL HEALTH MEDICATIONS|
|CYP2D6||Responsible for the metabolism of up to 25 percent of frequently prescribed drugs such as SSRIs, SNRIs, tricyclic antidepressants, and antipsychotics.9|
|CYP2C19||Essential in the breakdown of select SSRIs, tricyclic antidepressants, atypical antipsychotic and benzodiazepine medications.9|
- Bloom D et al. The Global Economic Burden of Non-Communicable Diseases. Geneva: World Economic Forum. 2011:1-48.
- Zandi PP and Judy JT. The Promise and Reality of Pharmacogenetics in Psychiatry. Psychiatr Clin North Am. 2010;33(1):181-224.
- Rush AJ et al. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. 2006; 163:1905-1917.
- Kelly K et al. Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues Clin Neurosci. 2008;10(4):409-18.
- Haddad PM et al. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014; 5:43-62.
- Velligan DI et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009; 70 Suppl 4:1-46; quiz 47-8.
- U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. 08/18/2014. Available at: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm.
- Hicks JK et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013; 93(5):402-8.
- Samer CF et al. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013; 17(3):165-84.